Labrie F, et al. - Through a placebo-controlled, prospective, double-blind and randomized study, experts determined the perks of daily intravaginal dehydroepiandrosterone (DHEA, prasterone) for 12 weeks on sexual function using the Female Sexual Function Index (FSFI) questionnaire. The FSFI domain desire improved over placebo by 0.24 unit, arousal by 0.42 unit, lubrication by 0.57 unit, orgasm by 0.32 unit, satisfaction by 0.44 unit, and pain at sexual activity by 0.62 unit. The total FSFI score, on the other hand, demonstrated the advantage of 2.59 units in the DHEA group in comparison with placebo or a 41.3% bigger chance vs placebo. Hence, all the six domains of the FSFI are got better above placebo, which confirmed the priorly perceived perks of intravaginal DHEA on female sexual dysfunction by an action exerted particularly at the level of the vagina, in the absence of biologically important alterations of serum steroids levels.